PMID- 29564742
OWN - NLM
STAT- MEDLINE
DCOM- 20190306
LR  - 20190306
IS  - 1573-7217 (Electronic)
IS  - 0167-6806 (Print)
IS  - 0167-6806 (Linking)
VI  - 170
IP  - 2
DP  - 2018 Jul
TI  - Immunohistochemistry and alternative FISH testing in breast cancer with HER2 
      equivocal amplification.
PG  - 321-328
LID - 10.1007/s10549-018-4755-5 [doi]
AB  - PURPOSE: While HER2 testing is well established in directing appropriate 
      treatment for breast cancer, a small percentage of cases show equivocal results 
      by immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH). 
      Alternative probes may be used in equivocal cases. We present a single 
      community-based institution's experience in further evaluating these cases. 
      PATIENTS AND METHODS: Between 2014 and 2016, 4255 samples were submitted for HER2 
      amplification testing by alternative probes, TP53, RAI1, and RARA. Of the 
      patients tested by FISH, 505/3908 (12.9%) also had IHC data. RESULTS: Most 
      (73.9%) FISH equivocal cases remained equivocal after IHC testing. However, 50.5% 
      of equivocal cases were classified as HER2 amplified by alternative probes. Most 
      cases were positive by more than one probe: 78% of positive cases by RAI1 and 
      73.9% by TP53. There was a significant difference between IHC and FISH 
      alternative testing (p < 0.0001) among the equivocal cases by conventional FISH 
      testing, 44% of IHC negative cases became positive while 36% of the positive IHC 
      cases became negative by alternative FISH testing. Available data showed that 41% 
      of patients were treated with palbociclib and were positive by alternative FISH. 
      CONCLUSION: The prevalence of double HER2 equivocal cases and the discrepancy 
      between IHC and alternative FISH testing suggest that FISH alternative testing 
      using both RAI1 and TP53 probes is necessary for conclusive classification. 
      Because almost half of FISH equivocal cases converted to HER2 amplified upon 
      alternative testing, clinical studies to determine the benefit of anti-HER2 
      therapy in these patients are urgently needed.
FAU - Agersborg, Sally
AU  - Agersborg S
AD  - NeoGenomics Laboratories, Research and Development, 31 Columbia, Aliso Viejo, CA, 
      92656, USA.
FAU - Mixon, Christopher
AU  - Mixon C
AD  - NeoGenomics Laboratories, Research and Development, 31 Columbia, Aliso Viejo, CA, 
      92656, USA.
FAU - Nguyen, Thanh
AU  - Nguyen T
AD  - NeoGenomics Laboratories, Research and Development, 31 Columbia, Aliso Viejo, CA, 
      92656, USA.
FAU - Aithal, Sramila
AU  - Aithal S
AD  - Cancer Treatment Centers of America, Philadelphia, PA, USA.
FAU - Sudarsanam, Sucha
AU  - Sudarsanam S
AD  - NeoGenomics Laboratories, Research and Development, 31 Columbia, Aliso Viejo, CA, 
      92656, USA.
FAU - Blocker, Forrest
AU  - Blocker F
AD  - NeoGenomics Laboratories, Research and Development, 31 Columbia, Aliso Viejo, CA, 
      92656, USA.
FAU - Weiss, Lawrence
AU  - Weiss L
AD  - NeoGenomics Laboratories, Research and Development, 31 Columbia, Aliso Viejo, CA, 
      92656, USA.
FAU - Gasparini, Robert
AU  - Gasparini R
AD  - NeoGenomics Laboratories, Research and Development, 31 Columbia, Aliso Viejo, CA, 
      92656, USA.
FAU - Jiang, Shiping
AU  - Jiang S
AD  - NeoGenomics Laboratories, Research and Development, 31 Columbia, Aliso Viejo, CA, 
      92656, USA.
FAU - Chen, Wayne
AU  - Chen W
AD  - NeoGenomics Laboratories, Research and Development, 31 Columbia, Aliso Viejo, CA, 
      92656, USA.
FAU - Hess, Gregory
AU  - Hess G
AD  - Symphony Health, Conshohocken, PA, USA.
FAU - Albitar, Maher
AU  - Albitar M
AUID- ORCID: 0000-0001-7661-9537
AD  - NeoGenomics Laboratories, Research and Development, 31 Columbia, Aliso Viejo, CA, 
      92656, USA. maheralbitar@gmail.com.
LA  - eng
PT  - Journal Article
DEP - 20180322
PL  - Netherlands
TA  - Breast Cancer Res Treat
JT  - Breast cancer research and treatment
JID - 8111104
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Receptors, Estrogen)
RN  - 0 (Receptors, Progesterone)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - *Biomarkers, Tumor
MH  - Breast Neoplasms/*genetics/*metabolism/pathology
MH  - Female
MH  - Gene Amplification
MH  - Humans
MH  - *Immunohistochemistry
MH  - *In Situ Hybridization, Fluorescence
MH  - Receptor, ErbB-2/*genetics/*metabolism
MH  - Receptors, Estrogen/metabolism
MH  - Receptors, Progesterone/metabolism
PMC - PMC5999182
OTO - NOTNLM
OT  - Breast cancer
OT  - Equivocal
OT  - FISH
OT  - HER2
OT  - IHC
COIS- Sally Agersborg, Christopher Mixon, Thanh Nguyen, Sucha Sudarsanam, Forrest 
      Blocker, Lawrence Weiss, Bob Gasparini, Shiping Jiang, Wayne Chen, and Maher 
      Albitar are employed by NeoGenomics, an oncology reference laboratory. Gregory 
      Hess is employed by Symphony Health, a medical data analytics company.
EDAT- 2018/03/23 06:00
MHDA- 2019/03/07 06:00
PMCR- 2018/03/22
CRDT- 2018/03/23 06:00
PHST- 2017/11/15 00:00 [received]
PHST- 2018/03/13 00:00 [accepted]
PHST- 2018/03/23 06:00 [pubmed]
PHST- 2019/03/07 06:00 [medline]
PHST- 2018/03/23 06:00 [entrez]
PHST- 2018/03/22 00:00 [pmc-release]
AID - 10.1007/s10549-018-4755-5 [pii]
AID - 4755 [pii]
AID - 10.1007/s10549-018-4755-5 [doi]
PST - ppublish
SO  - Breast Cancer Res Treat. 2018 Jul;170(2):321-328. doi: 10.1007/s10549-018-4755-5. 
      Epub 2018 Mar 22.